生物膜纳米载药系统在肿瘤免疫治疗中的应用进展(6)
[44] CHU D，DONG X，SHI X，et al. Neutrophil-based drug delivery systems[J]. Adv Mater，2018.DOI：10.1002/adma. 201706245.
[45] OLSON DJ，LUKE JJ. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development[J]. Immunotherapy，2019，11(3)：155-159.
[46] SZCZERBA BM，CASTRO-GINER F，VETTER M，et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature，2019，566(7745)：553-557.
[47] KANG T，ZHU Q，WEI D，et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis[J]. ACS Nano，2017，11(2)：1397-1411.
[48] QUARANTA V，SCHMID MC. Macrophage-mediated subversion of anti-tumour immunity[J]. Cell，2019.DOI：10.3390/cells8070747.
[49] CHOO YW，KANG M，KIM HY，et al. M1 macrophage- derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors[J]. ACS Nano，2018，12(9)：8977-8993.
[50] JOYCE JA，REARON DT. T cell exclusion，immune privilege，and the tumor microenvironment[J]. Science，2015，348(6230)：74-80.
[51] GAMMON JM，DOLD NM，JEWELL CM. Jewell，improving the clinical impact of biomaterials in cancer immunotherapy[J]. Oncotarget，2016，7(13)：15421-15443.
[52] LIU J，ZHANG R，XU ZP. Nanoparticle-based nanomedicines to promote cancer immunotherapy：recent advances and future directions[J]. Small，2019.DOI：10.1002/smll. 201900262.
(收稿日期：2019-10-17 修回日期：2020-01-10)
(編辑：唐晓莲), http://www.100md.com(田野 张阳 王骁勇 刘刚)
[45] OLSON DJ，LUKE JJ. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development[J]. Immunotherapy，2019，11(3)：155-159.
[46] SZCZERBA BM，CASTRO-GINER F，VETTER M，et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature，2019，566(7745)：553-557.
[47] KANG T，ZHU Q，WEI D，et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis[J]. ACS Nano，2017，11(2)：1397-1411.
[48] QUARANTA V，SCHMID MC. Macrophage-mediated subversion of anti-tumour immunity[J]. Cell，2019.DOI：10.3390/cells8070747.
[49] CHOO YW，KANG M，KIM HY，et al. M1 macrophage- derived nanovesicles potentiate the anticancer efficacy of immune checkpoint inhibitors[J]. ACS Nano，2018，12(9)：8977-8993.
[50] JOYCE JA，REARON DT. T cell exclusion，immune privilege，and the tumor microenvironment[J]. Science，2015，348(6230)：74-80.
[51] GAMMON JM，DOLD NM，JEWELL CM. Jewell，improving the clinical impact of biomaterials in cancer immunotherapy[J]. Oncotarget，2016，7(13)：15421-15443.
[52] LIU J，ZHANG R，XU ZP. Nanoparticle-based nanomedicines to promote cancer immunotherapy：recent advances and future directions[J]. Small，2019.DOI：10.1002/smll. 201900262.
(收稿日期：2019-10-17 修回日期：2020-01-10)
(編辑：唐晓莲), http://www.100md.com(田野 张阳 王骁勇 刘刚)